Net profit of INKON Life Technology 2015-2022
In 2022, INKON Life Technology generated a net loss of 596 million yuan. Formerly known as Starmap Medicine, the company is a subsidiary of Haier Group and focuses on high-tech oncology equipment and cancer treatment. INKON Life Technology was incubated by Haier which currently holds a controlling stake of 40 percent of shares.